Weight-loss drug semaglutide does not slow Alzheimer’s disease, two clinical trials find
Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer’s disease, finds the first large Phase III randomized controlled trials on the topic published in The Lancet.
Almost half of those stopping GLP-1 weight-loss drugs keep the weight off
Heart Benefits From GLP-1 Drugs Fade After Stopping, Study Finds
FRIDAY, March 20, 2026 — Drugs like Ozempic and Mounjaro are known to lower the risk of heart attack and stroke, but a new study suggests those benefits may not last if people stop taking them.Researchers found that heart risks begin to rise again w…
STAT+: Pharmalittle: We’re reading about TrumpRx expectations, a high-dose version of Wegovy, and more
And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…
What happens after Ozempic shocked researchers
Stopping popular weight-loss injections like Ozempic or Mounjaro might not trigger the dramatic rebound many fear. A large real-world study of nearly 8,000 patients found that most people who discontinue these drugs manage to keep the weight off—or even continue losing—by restarting treatment, switching medications, or adopting lifestyle changes. While earlier clinical trials suggested rapid weight regain, this new evidence paints a more hopeful picture.
High-Dose Wegovy Wins FDA Approval
(MedPage Today) — The FDA approved a higher dose of the GLP-1 receptor agonist semaglutide for weight loss, dubbed Wegovy HD, the agency announced on Thursday.
The once-weekly injectable will come in a 7.2-mg dose — three times the strength…
Lilly’s Triple Agonist, Retatrutide, Demonstrated Significant Reductions in A1C and Weight in First Phase 3 Trial for Treatment of Type 2 Diabetes
INDIANAPOLIS, March 19, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced positive topline results from TRANSCEND-T2D-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational…
Novo’s High Dose Wegovy Scores FDA Priority Voucher Program’s 4th Nod
With the approval of Wegovy HD, Novo Nordisk joins Johnson & Johnson, Boehringer Ingelheim and USAntibiotics as beneficiaries of the FDA’s Commissioner’s National Priority Voucher program, which aims to review products that align with certain national priorities in less than two months.
Novo wins FDA approval for high-dose Wegovy under commissioner’s voucher
The FDA approved a high-dose version of Novo Nordisk’s blockbuster weight loss injection Wegovy, giving its go-ahead about two months faster than normal thanks to a voucher received from the commissioner’s program.
Thursday’s approval is …
STAT+: Novo Nordisk’s high-dose Wegovy approved in the U.S.
A high-dose version of Novo Nordisk’s injectable obesity drug Wegovy received U.S. approval.